Author

P. Chaltin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:drug response / drug discovery· 4 Research Focus:host-pathogen & immune response· 2 Organism:virus· 2 Organism:bacteria (other)· 1 Assay:bulk RNA-seq· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

A. Marchand· 5 shared D. Bardiot· 3 shared D. Jochmans· 3 shared J. Neyts· 3 shared A. Jekle· 2 shared A. Stoycheva· 2 shared B. Vanmechelen· 2 shared C. Liu· 2 shared

Activity by Year

2018-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

A. Marchand

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor in vitro and confer resistance to nirmatrelvir

D. Jochmans, C. Liu, K. Donckers, A. Stoycheva, S. Boland, S. K. Stevens, C. De Vita, B. Vanmechelen, P. Maes, B. S. Trüeb, N. Ebert, V. Thiel, S. De Jonghe, L. Vangeel, D. Bardiot, , K. Vandyck

This paper identifies three substitutions in SARS-CoV-2 3CLpro that confer resistance to nirmatrelvir and other 3CLpro inhibitors in vitro.

bioRxiv · Jun 7, 2022 · PreprintMicrobiology

Identification of novel Ebola virus inhibitors using biologically contained virus

B. Vanmechelen, J. Stroobants, W. Chiu, J. Schepers, A. Marchand, P. Chaltin, K. Vermeire, P. Maes

This study screens over 4,200 small-molecule compounds against biologically contained Ebola virus to identify novel inhibitors.

bioRxiv · Dec 9, 2021Microbiology

ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model

K. Vandyck, R. Abdelnabi, K. Gupta, D. Jochmans, A. Jekle, J. Deval, D. Misner, D. Bardiot, C. S. Foo, C. Liu, S. Ren, L. Beigelman, L. M. Blatt, S. Boland, L. Vangeel, , J. Neyts

This study evaluates ALG-097111, a selective SARS-CoV-2 3CLpro inhibitor, showing potent in vitro activity and significant in vivo antiviral effects in Syrian hamsters.

bioRxiv · Feb 14, 2021Microbiology

Small-molecule antibiotic inhibitors of post-translational protein secretion

A. Economou, E. Burchacka, L. Angus, A. Marchand, M. B. Hamed, J. De Geyter, M. S. Loos, J. Anne, H. Klaassen, P. Chaltin, S. Karamanou

This study identifies small-molecule inhibitors of the bacterial Sec secretion pathway through a high-throughput screen, revealing compounds with antibacterial activity against multiple Gram-positive and Gram-negative species.

bioRxiv · Nov 17, 2020 · PreprintMicrobiology

Differential Antiviral Activities of RSV Inhibitors in Human Airway Epithelium

C. Mirabelli, M. Jaspers, M. Boon, M. Jorissen, M. Koukni, D. Bardiot, P. Chaltin, A. Marchand, J. Neyts, D. Jochmans

This study evaluates the antiviral efficacy of RSV inhibitors in a 3D-human airway epithelium model, showing that replication inhibitors are more effective than fusion inhibitors even when treatment is delayed.

bioRxiv · Jan 19, 2018Microbiology